Placebo-controlled phase 1 trial: oral PCSK9 inhibitor laroprovstat was well tolerated; after a rosuvastatin 20 mg run-in, laroprovstat 1 mg and 30 mg daily for 28 days lowered LDL-C by 29% and 51% from baseline in participants with hypercholesterolaemia.
RCT
Vega et al. Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients